Plain-English translation of NCT06010875 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of immunotherapy called CD70-targeted CAR-T cells. These are immune cells from your own body that are grown in a lab and taught to recognize and attack cancer cells. The study will test whether this treatment is safe and how well it works in people with advanced cancers that have stopped responding to other treatments.
Many people with advanced kidney, ovarian, cervical, or other solid cancers run out of standard treatment options when their cancer stops responding to chemotherapy, targeted drugs, or other standard therapies. This treatment was designed to offer a new option for patients in this difficult situation by harnessing their own immune system to fight back.
You likely qualify if…
You likely don't qualify if…
If you qualify, your own immune cells will be collected through a simple blood draw or apheresis procedure. These cells will be sent to a lab where they are grown and modified to recognize your cancer. You will then receive the cells back as an infusion—either through a vein in your arm or directly into your abdomen, depending on which group you are in. The study has two phases: first, researchers test different doses to find the safest level, then they enroll more patients to confirm that dose works well. You will have regular visits to monitor your health and your cancer's response to treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chongqing Precision Biotech Co., Ltd
Collaborators
The First Affiliated Hospital of Nanchang University
Enrollment target
~48 participants
Started
November 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fei Li, M.D
The First Affiliated Hospital of Nanchang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.